The Impact of Community and Patient Engagement Practices on Vaccine Confidence in the United States
Conditions: Vaccine Hesitancy Interventions: Behavioral: Community Engagement Practice; Behavioral: Patient-Centric Protocol Element Sponsors: Tufts University; Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2024 Category: Research Source Type: clinical trials
Post Pandemic Pneumococcal Carriage Among Children and Adults
Conditions: Pneumococcal Carriage Sponsors: University of Central Florida; Merck Sharp& Dohme Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2024 Category: Research Source Type: clinical trials
PSMA Therapy and Immunotherapy in Kidney Cancer
Conditions: Metastatic Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma Interventions: Drug: Pembrolizumab; Drug: 177Lu-PNT2002; Drug: (F-18)-DCFPyL Sponsors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Merck Sharp& Dohme LLC; Lantheus Medical Imaging Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
Conditions: Extensive Stage-small Cell Lung Cancer Interventions: Drug: Ifinatamab deruxtecan; Drug: Atezolizumab; Drug: Carboplatin; Drug: Etoposide Sponsors: Daiichi Sankyo; Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
A Study to Evaluate MK-2870 in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
Conditions: Gastroesophageal Cancer Interventions: Biological: MK-2870; Drug: Trifluridine-Tipiracil; Drug: Irinotecan; Drug: Paclitaxel; Drug: Docetaxel Sponsors: Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
Substudy 01A: Safety and Efficacy of MK-5684-based Treatment Combinations or MK-5684 Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
Conditions: Prostatic Neoplasms, Castration-Resistant Interventions: Drug: MK-5684; Drug: Olaparib; Drug: Docetaxel; Drug: Cabazitaxel Sponsors: Merck Sharp& Dohme LLC; Orion Corporation, Orion Pharma Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2024 Category: Research Source Type: clinical trials
Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer
Conditions: Urologic Neoplasms; Urogenital Neoplasms; Male Urogenital Diseases; Penile Cancer; Penile Squamous Cell Carcinoma; Locally Advanced Penile Carcinoma Interventions: Drug: Carboplatin/Paclitaxel; Drug: Pembrolizumab; Procedure: Partial or total penectomy with inguinal and/or pelvic lymph node dissection Sponsors: The Netherlands Cancer Institute; Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2024 Category: Research Source Type: clinical trials
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
Conditions: Thrombocythemia, Essential; Primary Myelofibrosis; Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis; Polycythemia Vera Interventions: Drug: Bomedemstat Sponsors: Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 8, 2024 Category: Research Source Type: clinical trials
A Phase I/II Single-arm Trial of Azenosertib (ZN-c3) Combined With Carboplatin and Pembrolizumab in Patients With Metastatic Triple-negative Breast Cancer (ZAP-IT)
Conditions: Breast Cancer; Breast Cancer Female; Triple Negative Breast Cancer; Hormone Receptor Negative Malignant Tumor Breast Triple; HER2-negative Breast Cancer Interventions: Drug: Azenosertib; Drug: Carboplatin; Drug: Pembrolizumab Sponsors: Filipa Lynce, MD; Merck Sharp& Dohme LLC; Zentalis Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 8, 2024 Category: Research Source Type: clinical trials
129 Xenon Imaging in Patients Treated With Sotatercept
Conditions: Pulmonary Hypertension; Pulmonary Arterial Hypertension Interventions: Drug: 129Xe Hyperpolarized Sponsors: Bastiaan Driehuys; Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 8, 2024 Category: Research Source Type: clinical trials
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with Keytruda (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
RAHWAY, N.J.--(BUSINESS WIRE) April 4, 2024 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced it has initiated a Phase 3 clinical trial evaluating MK-1084, an investigational oral selective KRAS G12C... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 4, 2024 Category: Pharmaceuticals Source Type: clinical trials
A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004)
Conditions: Non-small Cell Lung Cancer Interventions: Drug: MK-1084; Other: Placebo; Biological: Pembrolizumab Sponsors: Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 3, 2024 Category: Research Source Type: clinical trials
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients With Platinum-Resistant Ovarian Cancer
BASKING RIDGE, N.J.& RAHWAY, N.J., April 3, 2024– Daiichi Sankyo (TSE: 4568) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the first patient has been dosed in... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 3, 2024 Category: Pharmaceuticals Source Type: clinical trials
Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase - Producing Pathogens
Conditions: Febrile Neutropenia Interventions: Drug: Ceftolozane-Tazobactam; Drug: Meropenem Sponsors: Benefic ência Portuguesa de São Paulo; Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials
